Chemical Property of 2-Chloro-N-[4-chloro-3-(2-pyridinyl)phenyl]-4-(methylsulfonyl)benzamide
Chemical Property:
- Vapor Pressure:1.22E-12mmHg at 25°C
- Refractive Index:1.64
- Boiling Point:561.6°C at 760 mmHg
- PKA:10.72±0.70(Predicted)
- Flash Point:293.4°C
- PSA：84.51000
- Density:1.440
- LogP:5.86500
- Storage Temp.:-20°
- Solubility.:Soluble in DMSO (up to 200 mg/ml) or in Ethanol (up to 10 mg/ml with warming)
- Purity/Quality:
-
99%, *data from raw suppliers
Vismodegib *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Useful:
-
Description
In January 2012, the US FDA approved vismodegib (also referred to as
GDC-0449) for the treatment of adults with metastatic basal cell carcinoma
(BCC), with locally advanced BCC that has recurred following surgery or
who are not candidates for surgery or radiation. Vismodegib inhibits the Hh sig?naling pathway by functioning as an antagonist of SMO thereby inhibiting the activation of Hedgehog target genes, resulting in decreased downstream pro?duction of proliferation factors. The IC50 of vismodegib in a Hedgehog?responsive cell line derived from human embryonic palatal mesenchyme cells was 2.8 nM. In preclinical in vivostudies, vismodegib at 12.5 mg/kg (bid) caused complete regression of tumors in a Hh pathway dependent medulloblas?tomaallograft model generated from Ptch+/-mice. A synthesis of vismodegib starting from 2-chloro-5-nitro aniline and employing a Negishi coupling with 2-pyridyl zinc iodide as a key step has been reported.
-
Uses
Targets the Hedgehog (Hh) pathway. Inhibition of the Hh signaling may be effective in the treatment and prevention of many types of human cancers. Vismodegib (GDC-0449) is a potent, novel and specific hedgehog inhibitor with IC50 of 3 nM and also inhibits P-gp with IC50 of 3.0 μM. Vismodegib targets the Hedgehog (Hh) pathway. Inhibition of the Hh signaling may be effective in the treatment and prevention of many types of human cancers. Potent Hedgehog inhibitor.
-
Clinical Use
Antineoplastic agent: Treatment of basal cell carcinoma which is inappropriate for surgery or radiotherapy
-
Drug interactions
Potentially hazardous interactions with other drugs
Antibacterials: concentration possibly reduced by
rifampicin - avoid.
Antidepressants: concentration possibly reduced by
St John’s wort - avoid.
Antiepileptics: concentration possibly reduced by
carbamazepine, fosphenytoin and phenytoin - avoid.
Antipsychotics: avoid with clozapine, increased risk
of agranulocytosis.
